Title

Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy
  • Phase

    Phase 3
  • Study Type

    Interventional
  • Status

    Completed No Results Posted
  • Intervention/Treatment

    ranirestat ...
  • Study Participants

    500
This is a safety and efficacy trial of ranirestat(AS-3201) which is an aldose reductase inhibitor in patients with diabetic sensorimotor polyneuropathy.
Study Started
Oct 31
2004
Study Completion
Sep 30
2006
Last Update
Jan 14
2008
Estimate

Drug ranirestat, (AS-3201)

Criteria

Inclusion Criteria:

Patients with the following may enter:

Clinical signs and symptoms (footpain, numbness, tingling, weakness, etc.) of symmetrical distal Diabetic Sensorimotor Polyneuropathy with diagnosis by Nerve Conduction Tests and/or Quantitative Sensory Test.

18 to 70 years old of either sex and any race
Type I or Type II, insulin-dependent or non insulin-dependent diabetes for at least six months prior to study entry
Healthy in general
No hospitalizations for diabetic control or episodes of ketoacidosis for three months prior to screening
Female patients of childbearing potential must have a negative serum pregnancy test

Exclusion Criteria:

Known non-diabetic causes of neuropathic symptoms
Diabetic patients with no neuropathy or severe neuropathy
Used any Aldose Reductase Inhibitors within one year of screening
Clinically significant illness including unstable cardiac, pulmonary, hematologic, hepatic, renal, or neoplastic disease
A history of systemic carcinoma within five years of screening
A history of epilepsy or serious head injury
A history or evidence of drug or alcohol abuse
Test positive at screening for hepatitis B surface antigen or hepatitis C antibody or have a history of a positive result, or patients with evidence of significant hepatic insufficiency
A history of known or suspected diagnosis of AIDS, or have tested seropositive for HIV antibody or antigen previously
No Results Posted